Cargando…
Pancreatic Cancers with High Grade Tumor Budding Exhibit Hallmarks of Diminished Anti-Tumor Immunity
SIMPLE SUMMARY: Pancreatic cancer, in its most common manifestation pancreatic ductal adenocarcinoma (PDAC), is a uniquely lethal disease with very limited treatment options and few prognostic biomarkers. Tumor budding is a proven independent, adverse prognostic factor in many tumor types including...
Autores principales: | Sadozai, Hassan, Acharjee, Animesh, Gruber, Thomas, Gloor, Beat, Karamitopoulou, Eva |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961597/ https://www.ncbi.nlm.nih.gov/pubmed/33806316 http://dx.doi.org/10.3390/cancers13051090 |
Ejemplares similares
-
Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer
por: Sadozai, Hassan, et al.
Publicado: (2021) -
Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC)
por: Karamitopoulou, Eva, et al.
Publicado: (2013) -
Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an independent prognostic factor in surgically resected pancreatic ductal adenocarcinoma
por: Wartenberg, Martin, et al.
Publicado: (2015) -
Role of Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Is Tumor Budding the Missing Link?
por: Karamitopoulou, Eva
Publicado: (2013) -
Tumor budding cells, cancer stem cells and epithelial-mesenchymal transition-type cells in pancreatic cancer
por: Karamitopoulou, Eva
Publicado: (2013)